孕激素受體膜成分1在子宮內(nèi)膜癌中表達(dá)及對(duì)細(xì)胞增殖的影響

于麗 曾楨 李婷 廖秦平

【摘要】目的：檢測(cè)子宮內(nèi)膜癌組織中孕激素受體膜成分1（PGRMC1）的蛋白表達(dá)特點(diǎn)，分析其臨床意義；并探討PGRMC1對(duì)子宮內(nèi)膜癌細(xì)胞增殖調(diào)控的影響。方法：采用蛋白質(zhì)免疫印跡法（Western blot）檢測(cè)70例子宮內(nèi)膜癌組織及28例對(duì)照子宮內(nèi)膜組織中PGRMC1蛋白表達(dá)水平；應(yīng)用細(xì)胞免疫組化方法檢測(cè)三種人子宮內(nèi)膜癌細(xì)胞系中PGRMC1的表達(dá)定位；將PGRMC1的小分子抑制劑Ag205以不同濃度分別刺激人子宮內(nèi)膜癌細(xì)胞Ishikawa、Hec-1A、KLE 72小時(shí)，應(yīng)用CCK-8（cell counting kit 8）方法檢測(cè)Ag205對(duì)細(xì)胞活力的影響。結(jié)果：子宮內(nèi)膜癌組織中PGRMC1表達(dá)較正常內(nèi)膜顯著升高（P=0.038）；PGRMC1在各期子宮內(nèi)膜癌組織中的表達(dá)無(wú)差異，但在Ⅰ期患者中，PGRMC1在Ⅰa期表達(dá)較Ⅰb期顯著高（P=0.019）；PGRMC1表達(dá)與子宮內(nèi)膜癌組織中ER表達(dá)水平相關(guān)（P=0.015），但與分化程度、淋巴結(jié)轉(zhuǎn)移及脈管癌栓無(wú)關(guān)，與 PR、p53、Ki-67及bcl-2表達(dá)亦無(wú)顯著相關(guān)性；20μM Ag205顯著抑制三種子宮內(nèi)膜癌細(xì)胞的增殖活力，其中以KLE細(xì)胞的抑制作用最明顯，從最低濃度（5μM）即出現(xiàn)抑制效應(yīng)，并隨濃度增加抑制作用逐步增強(qiáng)。結(jié)論：子宮內(nèi)膜癌內(nèi)膜中PGRMC1表達(dá)顯著增高；增高的PGRMC1參與調(diào)控子宮內(nèi)膜癌細(xì)胞的增殖活性。

【關(guān)鍵詞】子宮內(nèi)膜癌；孕激素受體膜成分1；增殖活力；蛋白質(zhì)免疫印跡法

The expression of PGRMC1 in endometrial cancer andits effect on endometrial cancer cell proliferationYU Li， ZENG Zhen， LI Ting， LIAO Qinping△. Department of Obstetrics and Gynecology， Peking University First Hospital， Beijing 100034， China

【Abstract】Objectives： To investigate the expression pattern of progesterone receptor membrane component 1 （PGRMC1） in endometrial carcinoma （EC）， and evaluate the probable role of PGRMC1 in the proliferation of endometrial cancer cells. Methods： 70 endometrial cancer tissues and 28 noncancerous endometrial tissues were collected as experimental group and control group respectively. The expression of PGRMC1 was detected by Western blot. Three endometrial cancer cell lines were cultured in vitro， then the expression location of PGRMC1 were tested by immunohistochemistry. The cell viability was detected by CCK-8 after treatment with Ag205 for 72 hours individually， which was the specific inhibitor of PGRMC1. Results： The expression of PGRMC1 was significantly higher in EC patients than control group （P=0.038）. There was no difference among different stages， but the expression of PGRMC1 was significantly higher in patients with stage Ia than stage Ib （P=0.019）. In endometrial carcinoma the increase of PGRMC1 was detected in those with high ER status （P=0.015）. PGRMC1 expression had no relationship with lymph node metastasis or vascular invasion， and was unrelated to the expression of PR， p53， Ki-67， bcl-2. The proliferation of three endometrial cancer cell lines was all heavily inhibited by 20μM Ag205. In KLE cells Ag205 showed the strongest growth repression， since from 5μM the repression effect began to appear. Conclusion： The expression of PGRMC1 is significantly higher in EC patients than that in control group. The over-expression of PGRMC1 in endometrial carcinoma may play a role in the proliferation activity of endometrial cancer cells.

【Key words】Endometrial carcinoma； Progesterone receptor membrane component 1 （PGRMC1）； Proliferation activity； Western blot

【中圖分類號(hào)】R737.33【文獻(xiàn)標(biāo)志碼】A

子宮內(nèi)膜癌是女性生殖道常見(jiàn)惡性腫瘤之一，最新統(tǒng)計(jì)數(shù)據(jù)顯示，子宮內(nèi)膜癌的發(fā)病率已經(jīng)超過(guò)子宮頸癌和卵巢癌發(fā)病的總和，成為嚴(yán)重威脅女性健康的疾病[1]。子宮內(nèi)膜癌發(fā)生及惡性進(jìn)展與雌、孕激素作用失衡密切相關(guān)，近年來(lái)研究發(fā)現(xiàn)性……